Short Interest in Enfusion, Inc. (NYSE:ENFN) Rises By 14.6%

Enfusion, Inc. (NYSE:ENFN) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 1,810,000 shares, an increase of 14.6% from the May 31st total of 1,580,000 shares. Based on an average daily volume of 332,700 shares, the short-interest ratio is currently 5.4 days. Approximately 3.7% of the shares of the company are short sold.

Enfusion Stock Down 0.8 %

ENFN opened at $8.52 on Monday. The stock has a market cap of $1.09 billion, a PE ratio of 284.09, a P/E/G ratio of 1.98 and a beta of 0.92. Enfusion has a 52 week low of $7.52 and a 52 week high of $11.56. The business’s fifty day simple moving average is $9.07 and its 200 day simple moving average is $9.05.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The business had revenue of $48.05 million for the quarter, compared to analysts’ expectations of $47.67 million. During the same quarter in the previous year, the company earned $0.04 earnings per share. As a group, equities analysts anticipate that Enfusion will post 0.09 earnings per share for the current year.

Insider Activity at Enfusion

In related news, insider Bronwen Bastone sold 10,539 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total value of $86,103.63. Following the transaction, the insider now owns 217,154 shares in the company, valued at $1,774,148.18. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Enfusion news, insider Bronwen Bastone sold 10,539 shares of the business’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $8.17, for a total transaction of $86,103.63. Following the sale, the insider now owns 217,154 shares of the company’s stock, valued at approximately $1,774,148.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Deirdre Somers sold 4,629 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $8.40, for a total transaction of $38,883.60. Following the sale, the director now directly owns 43,312 shares in the company, valued at approximately $363,820.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,318 shares of company stock worth $296,688. Insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

Several institutional investors have recently added to or reduced their stakes in ENFN. California State Teachers Retirement System boosted its position in Enfusion by 11.0% during the 1st quarter. California State Teachers Retirement System now owns 36,002 shares of the company’s stock valued at $333,000 after acquiring an additional 3,556 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Enfusion during the 1st quarter valued at approximately $102,000. Quadrature Capital Ltd bought a new stake in Enfusion during the 1st quarter valued at approximately $109,000. Vanguard Group Inc. boosted its position in Enfusion by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock valued at $33,792,000 after acquiring an additional 51,670 shares in the last quarter. Finally, Bleakley Financial Group LLC bought a new stake in Enfusion during the 1st quarter valued at approximately $176,000. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ENFN has been the topic of several research analyst reports. Bank of America upped their price target on shares of Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a report on Wednesday, March 13th. Morgan Stanley began coverage on shares of Enfusion in a report on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.